Arlene M Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/710990/publications.pdf

Version: 2024-02-01

29 papers 1,334 citations

16 h-index 26 g-index

29 all docs

29 docs citations

29 times ranked 1377 citing authors

#	Article	IF	CITATIONS
1	Clinical Trials and Medical Care: Defining the Therapeutic Misconception. PLoS Medicine, 2007, 4, e324.	8.4	376
2	Characterizing biobank organizations in the U.S.: results from a national survey. Genome Medicine, 2013, 5, 3.	8.2	157
3	Therapeutic misconception in early phase gene transfer trials. Social Science and Medicine, 2006, 62, 239-253.	3.8	113
4	Ethical, Legal, and Social Concerns About Expanded Newborn Screening: Fragile X Syndrome as a Prototype for Emerging Issues. Pediatrics, 2008, 121, e693-e704.	2.1	92
5	Consent Forms and the Therapeutic Misconception: The Example of Gene Transfer Research. IRB: Ethics & Human Research, 2005, 27, 1.	0.8	79
6	The Invisible Hand in Clinical Research: The Study Coordinator's Critical Role in Human Subjects Protection. Journal of Law, Medicine and Ethics, 2002, 30, 411-419.	0.9	69
7	A place for genetic uncertainty: Parents valuing an unknown in the meaning of disease. Social Science and Medicine, 2007, 65, 1082-1093.	3.8	68
8	The many meanings of care in clinical research. Sociology of Health and Illness, 2006, 28, 695-712.	2.1	60
9	Changing perspectives on the benefits of newborn screening. Mental Retardation and Developmental Disabilities Research Reviews, 2006, 12, 270-279.	3.6	48
10	Uncertain benefit: investigators' views and communications in early phase gene transfer trials. Molecular Therapy, 2004, 10, 225-231.	8.2	44
11	Stewardship Practices of U.S. Biobanks. Science Translational Medicine, 2013, 5, 215cm7.	12.4	34
12	Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice. American Journal of Bioethics, 2015, 15, 3-14.	0.9	30
13	Consent forms and the therapeutic misconception: the example of gene transfer research. IRB: Ethics & Human Research, 2005, 27, 1-8.	0.8	30
14	Assessing Benefits in Clinical Research: Why Diversity in Benefit Assessment Can Be Risky. IRB: Ethics & Human Research, 2003, 25, 1.	0.8	26
15	Vulnerability to Influence: A Two-Way Street. American Journal of Bioethics, 2004, 4, 50-52.	0.9	18
16	Which Results to Return: Subjective Judgments in Selecting Medically Actionable Genes. Genetic Testing and Molecular Biomarkers, 2017, 21, 184-194.	0.7	17
17	"Forward-Thinking―in U.S. Biobanking. Genetic Testing and Molecular Biomarkers, 2017, 21, 148-154.	0.7	12
18	Transitions in Care for Infants with Trisomy 13 or 18. American Journal of Perinatology, 2017, 34, 887-894.	1.4	11

#	Article	IF	CITATIONS
19	Assessing benefits in clinical research: why diversity in benefit assessment can be risky. IRB: Ethics & Human Research, 2003, 25, 1-8.	0.8	10
20	Parents' Online Portrayals of Pediatric Treatment and Research Options. Journal of Empirical Research on Human Research Ethics, 2009, 4, 73-87.	1.3	8
21	Genomic Research with the Newly Dead: A Crossroads for Ethics and Policy. Journal of Law, Medicine and Ethics, 2014, 42, 220-231.	0.9	8
22	Exception from Informed Consent for Emergency Research: Drawing on Existing Skills and Experience. IRB: Ethics & Human Research, 1998, 20, 1.	0.8	7
23	Membership recruitment and training in health care ethics committees: Results from a national pilot survey. AJOB Empirical Bioethics, 2017, 8, 161-169.	1.6	7
24	Is Real-Time ELSI Realistic?. AJOB Empirical Bioethics, 2020, 11, 134-144.	1.6	6
25	Addressing "Difficult Patient―Dilemmas: Possible Alternatives to the Mediation Model. American Journal of Bioethics, 2012, 12, 13-14.	0.9	2
26	Clarifying a Clinical Ethics Service's Value, the Visible and the Hidden. Journal of Clinical Ethics, 2019, 30, 251-261.	0.3	2
27	Trade-Secret Model: Legal Limitationsâ€"Response. Science, 2011, 333, 1575-1576.	12.6	0
28	Response to Open Peer Commentaries on "Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice― American Journal of Bioethics, 2015, 15, W6-W9.	0.9	0
29	Reconsidering scarce drug rationing: implications for clinical research. Journal of Medical Ethics, 2021, 47, e16-e16.	1.8	O